Aclaris Therapeutics, Inc. (ACRS)
3.38
-0.11
(-3.15%)
USD |
NASDAQ |
Oct 16, 10:38
Aclaris Therapeutics SG&A Expense (TTM) : 23.24M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.24M |
| March 31, 2026 | 22.58M |
| December 31, 2025 | 21.97M |
| September 30, 2025 | 21.35M |
| June 30, 2025 | 22.13M |
| March 31, 2025 | 21.50M |
| December 31, 2024 | 22.20M |
| September 30, 2024 | 25.46M |
| June 30, 2024 | 26.90M |
| March 31, 2024 | 30.47M |
| December 31, 2023 | 32.41M |
| September 30, 2023 | 31.34M |
| June 30, 2023 | 30.07M |
| March 31, 2023 | 27.82M |
| December 31, 2022 | 25.13M |
| September 30, 2022 | 24.93M |
| June 30, 2022 | 25.10M |
| March 31, 2022 | 24.89M |
| December 31, 2021 | 23.62M |
| September 30, 2021 | 21.57M |
| June 30, 2021 | 19.45M |
| March 31, 2021 | 19.16M |
| Date | Value |
|---|---|
| December 31, 2020 | 20.53M |
| September 30, 2020 | 21.44M |
| June 30, 2020 | 24.42M |
| March 31, 2020 | 26.32M |
| December 31, 2019 | 27.58M |
| September 30, 2019 | 28.41M |
| June 30, 2019 | 27.78M |
| March 31, 2019 | 40.80M |
| December 31, 2018 | 50.83M |
| September 30, 2018 | 56.68M |
| June 30, 2018 | 58.60M |
| March 31, 2018 | 45.44M |
| December 31, 2017 | 33.11M |
| September 30, 2017 | 25.30M |
| June 30, 2017 | 20.82M |
| March 31, 2017 | 16.64M |
| December 31, 2016 | 15.09M |
| September 30, 2016 | 12.81M |
| June 30, 2016 | 10.39M |
| March 31, 2016 | 7.236M |
| December 31, 2015 | 3.632M |
| September 30, 2015 | 1.232M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Corcept Therapeutics, Inc. | 556.47M |
| Alumis, Inc. | 77.08M |
| ANI Pharmaceuticals, Inc. | 324.76M |
| Veru, Inc. | 16.05M |
| Johnson & Johnson | 19.22B |